GlassScriptPhysician profile
Bihter Korbeci
NPI 1932540432
$2,283.03
in general payments reported to CMS, 2019-2025
32 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $54.93 · 2024: $17.73 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $345.54 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $232.92 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $176.54 | 2019-2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $176.46 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.01 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $134.29 | 2019-2025 | |
| Inspire Medical Systems, INC. | $117.37 | 2025 | Inspire |
| Intuitive Surgical, INC. | $109.68 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $80.71 | 2019-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $73.00 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $70.22 | 2019 | |
| Exact Sciences Corporation | $64.72 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $64.08 | 2019 | |
| Axsome Therapeutics, INC. | $42.74 | 2025 | Auvelity |
| Shield Therapeutics INC | $41.21 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.57 | 2025 | Koselugo |
| Bayer Healthcare Pharmaceuticals INC. | $37.51 | 2025 | |
| Sumitomo Pharma America, INC. | $37.48 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.86 | 2025 | Caplyta |
| Amarin Pharma, INC. | $32.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.59 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $26.10 | 2025 | Spravato |
| Insulet Corporation | $23.27 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $22.00 | 2019 | |
| Corcept Therapeutics | $20.67 | 2025 | Korlym |
| Gilead Sciences, INC. | $20.63 | 2025 | |
| Allergan, INC. | $17.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.08 | 2019 | |
| Abbvie INC. | $16.53 | 2025 | |
| Seqirus USA INC | $16.24 | 2025 | Flucelvax, Fluad |
| Almatica Pharma LLC | $14.60 | 2025 | Teriparatide, Loreev Xr |
| Arbor Pharmaceuticals, INC. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bihter Korbeci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.